开云app官网登录入口网页版-官方正版

#ROCK#

17篇内容 | 1013人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1710531, encodeId=98191e1053110, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病, objectType=article, longId=210383, objectId=687e210383ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=687e210383ae, replyNumber=0, likeNumber=77, createdTime=2021-05-31, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=687e210383ae, moduleTitle=J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=687e210383ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710530, encodeId=448e1e105302b, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性, objectType=article, longId=199169, objectId=79d81991691e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79d81991691e, replyNumber=0, likeNumber=75, createdTime=2020-12-20, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79d81991691e, moduleTitle=Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=79d81991691e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710529, encodeId=a7211e1052963, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025, objectType=article, longId=185345, objectId=196018534552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=196018534552, replyNumber=0, likeNumber=79, createdTime=2020-08-18, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=196018534552, moduleTitle=慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=196018534552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710527, encodeId=29001e10527c8, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Thorax：使用NLST数据对Brock模型进行外部验证和重新校准，以预测肺结节中癌症的概率, objectType=article, longId=162891, objectId=844716289121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=844716289121, replyNumber=0, likeNumber=61, createdTime=2019-10-27, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=844716289121, moduleTitle=Thorax：使用NLST数据对Brock模型进行外部验证和重新校准，以预测肺结节中癌症的概率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=844716289121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710528, encodeId=b5931e105285c, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究, objectType=article, longId=177384, objectId=b3ec1e73841a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ec1e73841a, replyNumber=0, likeNumber=112, createdTime=2020-03-04, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ec1e73841a, moduleTitle=拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b3ec1e73841a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710526, encodeId=5e421e10526a7, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Stem Cells Int：粘着斑激酶和ROCK信号转导是人类脂肪干细胞向成骨和成脂谱系分化的转换调节因子, objectType=article, longId=150565, objectId=9c611505655d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c611505655d, replyNumber=0, likeNumber=57, createdTime=2019-06-04, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c611505655d, moduleTitle=Stem Cells Int：粘着斑激酶和ROCK信号转导是人类脂肪干细胞向成骨和成脂谱系分化的转换调节因子, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c611505655d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710525, encodeId=d35d1e105254e, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Cell Death Dis：通过调节FGF2-RhoA/ROCK信号及血管化将骨髓间充质干细胞转化为组织工程骨移植物中的内皮细胞, objectType=article, longId=150190, objectId=eb5415019013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5415019013, replyNumber=0, likeNumber=67, createdTime=2018-11-23, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5415019013, moduleTitle=Cell Death Dis：通过调节FGF2-RhoA/ROCK信号及血管化将骨髓间充质干细胞转化为组织工程骨移植物中的内皮细胞, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb5415019013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710524, encodeId=c8211e1052483, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=NEJM：ROCK抑制剂培养角膜内皮细胞注射用于大泡性角膜病变的治疗, objectType=article, longId=132484, objectId=8728132484cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8728132484cc, replyNumber=0, likeNumber=79, createdTime=2018-08-26, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8728132484cc, moduleTitle=NEJM：ROCK抑制剂培养角膜内皮细胞注射用于大泡性角膜病变的治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8728132484cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710523, encodeId=fb111e10523cd, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=J Gastroen Hepatol：Rockall评分对消化性溃疡出血长期预后的影响, objectType=article, longId=125857, objectId=b21c12585e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b21c12585e18, replyNumber=0, likeNumber=52, createdTime=2018-04-24, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b21c12585e18, moduleTitle=J Gastroen Hepatol：Rockall评分对消化性溃疡出血长期预后的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b21c12585e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710522, encodeId=3ff41e1052232, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Scholar Rock融资4700万美元，给脊髓性肌萎缩症患者带来新希望, objectType=article, longId=125550, objectId=e8e81255507e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8e81255507e, replyNumber=0, likeNumber=53, createdTime=2018-01-17, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8e81255507e, moduleTitle=Scholar Rock融资4700万美元，给脊髓性肌萎缩症患者带来新希望, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e8e81255507e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710521, encodeId=79e51e1052125, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Gastroenterology：局部的ROCK抑制剂治疗肠纤维化梗阻, objectType=article, longId=102643, objectId=b7ac1026434e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7ac1026434e, replyNumber=0, likeNumber=71, createdTime=2018-02-25, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7ac1026434e, moduleTitle=Gastroenterology：局部的ROCK抑制剂治疗肠纤维化梗阻, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b7ac1026434e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710520, encodeId=25211e1052034, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）, objectType=article, longId=72726, objectId=3fcee272613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fcee272613, replyNumber=0, likeNumber=70, createdTime=2017-01-04, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fcee272613, moduleTitle=FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3fcee272613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710519, encodeId=0cb51e10519b7, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Circulation：房颤患者服用多种药物，脑卒中发生的风险真的很大吗（ROCKET AF研究）？, objectType=article, longId=61164, objectId=ca0061164af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0061164af, replyNumber=0, likeNumber=53, createdTime=2016-09-14, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0061164af, moduleTitle=Circulation：房颤患者服用多种药物，脑卒中发生的风险真的很大吗（ROCKET AF研究）？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ca0061164af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710518, encodeId=f8871e10518a9, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Rock Health报告：从预测性分析走向个性化医疗, objectType=article, longId=42032, objectId=92c242032af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92c242032af, replyNumber=0, likeNumber=68, createdTime=2015-03-29, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92c242032af, moduleTitle=Rock Health报告：从预测性分析走向个性化医疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=92c242032af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710517, encodeId=e5001e1051787, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=Cancer Res:ROCK抑制剂RKI-1447或抵抗乳腺癌, objectType=article, longId=8507, objectId=dd23850ee5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd23850ee5, replyNumber=0, likeNumber=69, createdTime=2012-10-30, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd23850ee5, moduleTitle=Cancer Res:ROCK抑制剂RKI-1447或抵抗乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dd23850ee5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710516, encodeId=75541e10516f8, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=ROCKET AF研究：肾功能不全房颤患者危险高, objectType=article, longId=3064, objectId=857a30647e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=857a30647e, replyNumber=0, likeNumber=70, createdTime=2011-12-09, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=857a30647e, moduleTitle=ROCKET AF研究：肾功能不全房颤患者危险高, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=857a30647e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710515, encodeId=2dfa1e10515b1, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, objectTitle=ROCKET AF研究房颤卒中预防，利伐沙班与华法林疗效相当, objectType=article, longId=2258, objectId=b0d02258d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0d02258d9, replyNumber=0, likeNumber=66, createdTime=2011-08-24, rootId=0, userName=12498dabm87暂无昵称, userId=a19831855420, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0d02258d9, moduleTitle=ROCKET AF研究房颤卒中预防，利伐沙班与华法林疗效相当, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b0d02258d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ROCK

2020-05-29

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

J Clin Oncol：ROCK2抑制剂贝鲁地尔可有效治疗难治性慢性移植物抗宿主病

2021-05-31

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性

2020-12-20

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025

2020-08-18

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Thorax：使用NLST数据对Brock模型进行外部验证和重新校准，以预测肺结节中癌症的概率

2019-10-27

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究

2020-03-04

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Stem Cells Int：粘着斑激酶和ROCK信号转导是人类脂肪干细胞向成骨和成脂谱系分化的转换调节因子

2019-06-04

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Cell Death Dis：通过调节FGF2-RhoA/ROCK信号及血管化将骨髓间充质干细胞转化为组织工程骨移植物中的内皮细胞

2018-11-23

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

NEJM：ROCK抑制剂培养角膜内皮细胞注射用于大泡性角膜病变的治疗

2018-08-26

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

J Gastroen Hepatol：Rockall评分对消化性溃疡出血长期预后的影响

2018-04-24

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Scholar Rock融资4700万美元，给脊髓性肌萎缩症患者带来新希望

2018-01-17

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Gastroenterology：局部的ROCK抑制剂治疗肠纤维化梗阻

2018-02-25

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）

2017-01-04

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Circulation：房颤患者服用多种药物，脑卒中发生的风险真的很大吗（ROCKET AF研究）？

2016-09-14

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Rock Health报告：从预测性分析走向个性化医疗

2015-03-29

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

Cancer Res:ROCK抑制剂RKI-1447或抵抗乳腺癌

2012-10-30

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

ROCKET AF研究：肾功能不全房颤患者危险高

2011-12-09

12498dabm87暂无昵称 (审核中...)

前往app查看评论内容

#ROCK#

ROCKET AF研究房颤卒中预防，利伐沙班与华法林疗效相当

2011-08-24

科室
- - 订阅+
  - 更多科室
工具
服务